In cancer, its effects vary by tumor type and receptor subtype; H2R is mostly protumorigenic (e.g., in CRC and GC) and H4R is mostly tumor‐suppressive (e.g., in CRC), with exceptions in some cases. Here, HRH2 is linked to neoplasm.